For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

To address esketamine's side effects, the FDA will require that the drug be given in the presence of a clinician so patients can be monitored for a few hours. "Because of [safety] concerns ...

The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...

Janssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a party drug – is to be reviewed by advisers to the FDA at a crunch ...

This is because the Food and Drug Administration (FDA) only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine.

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one roof would be ideal.

There is hope for your symptoms. The clinic also offer the FDA approved Spravato (Esketamine) for treatment resistant depression, anxiety, and PTSD. Call for inquiries. Immediate appointment times ...